Protalix BioTherapeutics
PLX
#8915
Rank
A$0.20 B
Marketcap
A$2.60
Share price
-1.14%
Change (1 day)
-1.37%
Change (1 year)

Revenue for Protalix BioTherapeutics (PLX)

Revenue in 2025 (TTM): A$95.26 Million

According to Protalix BioTherapeutics 's latest financial reports the company's current revenue (TTM ) is A$93.26 Million. In 2024 the company made a revenue of A$85.85 Million a decrease over the revenue in the year 2023 that were of A$96.13 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Protalix BioTherapeutics from 1999 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) A$95.26 M10.96%
2024 A$85.85 M-10.69%
2023 A$96.13 M37.32%
2022 A$70 M32.34%
2021 A$52.89 M-35.33%
2020 A$81.79 M4.71%
2019 A$78.11 M8.11%
2018 A$72.25 M193.18%
2017 A$24.64 M93.13%
2016 A$12.76 M-236.1%
2015 -A$9.38 Million-150.62%
2014 A$18.52 M43.52%
2013 A$12.9 M-61.04%
2012 A$33.12 M238.87%
2011 A$9.77 M56.42%
2010 A$6.24 M1346.89%
2009 A$0.43 M
2000 A$0 M-100%
1999 A$5.4 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Amicus Therapeutics
FOLD
A$0.90 B 866.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
A$4.03 B 4,230.57%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
A$94.52 B 101,252.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
A$25.25 B 26,980.78%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel